Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke
The LancetPublished 1 August 1997
Joanna M. Wardlaw, C P Warlow, Carl Counsell
Citations288
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A systematic review of all available randomised trials of thrombolytic therapy in acute ischaemic stroke found no objective evidence to suggest that tPA is safer than streptokinase or urokinase and the time window for effective treatment remains unclear.
Abstract
Thrombolysis requires further testing in large randomised trials because the risks seem substantial, and the benefit uncertain. The time window for effective treatment remains unclear. There is no objective evidence to suggest that tPA is safer than streptokinase; the apparent hazards and benefits may be similar when differences in trial design and baseline variables are accounted for.
Keywords
Medicine
New England Journal of MedicineTissue Plasminogen Activator for Acute Ischemic Stroke
11,541 Citations1995The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
The LancetMortality by cause for eight regions of the world: Global Burden of Disease Study
4,064 Citations1997Christopher Murray, Alan D López
The Global Burden of Disease Study (GBD) used various data sources and made corrections for miscoding of important diseases (eg, ischaemic heart disease) to estimate worldwide and regional cause-of-death patterns in 1990, and the estimates by cause provide a foundation for a more informed debate on public-health priorities.
BMJCollaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3,125 Citations1994Antiplatelet Trialists' Collaboration
There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events, so in each of the four main high risk categories overall mortality was significantly reduced.
JAMAIntravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke
2,362 Citations1995Werner Hacke
Intravenous thrombolysis in acute ischemic stroke is effective in improving some functional measures and neurologic outcome in a defined subgroup of stroke patients with moderate to severe neurologic deficit and without extended infarct signs on the initial CT scan, however, the identification of this subgroup is difficult.
The LancetIndications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
2,289 Citations1994Fibrinolytic Therapy Trialists' Collaborative Group
Borås Academic Digital Archive (University of Borås)Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
2,230 Citations1994Johan Herlitz
It is shown that fibrinolytic therapy can reduce mortality in patients with suspected acute myocardial infarction (AMI) and the indications for, and contraindications to, this therapy.
The LancetThe International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
1,890 Citations1997Peter Sandercock
Aspirinallocated patients had significantly fewer recurrent ischaemic strokes within 14 days with no significant excess of haemorrhagic strokes, so the reduction in death or non-fatal recurrent stroke with aspirin was significant.
JAMAA Comparison of Results of Meta-analyses of Randomized Control Trials and Recommendations of Clinical Experts
1,464 Citations1992Elliott M. Antman
Finding and analyzing all therapeutic trials in a given field has become such a difficult and specialized task that the clinical experts called on to summarize the evidence in a timely fashion need access to better databases and new statistical techniques to assist them.
The LancetRandomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
630 Citations1995Multicentre Acute Stroke Trial—Italy Group
New England Journal of MedicineThrombolytic Therapy with Streptokinase in Acute Ischemic Stroke
566 Citations1996The Multicenter Acute Stroke Trial — Europe Study Group
In patients with acute ischemic stroke, treatment with strePTokinase resulted in an increase in mortality, and the routine use of streptokinase cannot be recommended in acute isChemic stroke.
NeurologyIntravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke
479 Citations1992Etsuro Mori, Yukihiro Yoneda +7 more
The efficacy of intravenous infusion of rt-PA soon after the onset of stroke in producing rapid thrombolysis and neurologic recovery is supported and may be of particular value in patients withThromboembolic occlusion in the middle cerebral artery.
JAMAStreptokinase for Acute Ischemic Stroke With Relationship to Time of Administration
357 Citations1996Geoffrey A. Donnan
The administration of streptokinase within 4 hours of acute ischemic stroke increased morbidity and mortality at 3 months and treatment within 3 hours of stroke was safer and associated with significantly better outcomes than later treatment.
JAMAStreptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
294 Citations1996Geoffrey A. Donnan
Journal of the American Medical AssociationTHROMBOLYSIS WITH FIBRINOLYSIN IN CEREBRAL ARTERIAL OCCLUSION
208 Citations1958Bernard J. Sussman
Three patients with hemiplegia were treated by the slow intravenous infusion of fibrinolysin and the site of occlusion of the cerebral vessels was located in each case by arteriography, suggesting that the lesion was caused by anembolus originating in the fibrillating left atrium and that the embolus was a fresh thrombus most susceptible to the lytic agent.
StrokePatient preferences for stroke outcomes.
205 Citations1994Nadia Solomon, Henry A. Glick +3 more
Data from this study are useful in interpreting studies that report stroke and death, in designing new studies that measure stroke in at-risk populations, and in helping patients reach treatment decisions about therapies designed to prevent strokes.
StrokeThrombolysis in acute ischemic stroke: does it work?
186 Citations1992Joanna M. Wardlaw, Charles Warlow
Analysis of all published studies shows that there does not appear to be an excess risk of hemorrhagic transformation of the cerebral infarct or of severe edema formation and the present evidence is sufficiently encouraging to warrant proper testing of thrombolysis in sufficiently large and well-designed randomized clinical trials to influence clinical practice.
StrokePilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.
183 Citations1993E. Clarke Haley, Thomas Brott +8 more
Preliminary observations suggest that recombinant tissue-type plasminogen activator treatment within 90 minutes may be associated with early neurological improvement and potentially serious short-term risks of this treatment can be assessed in relation to meaningful long-term benefit.
BMJThe relation between treatment benefit and underlying risk in meta-analysis
169 Citations1996Stephen J. Sharp, Simon G. Thompson +1 more
Meta-analyses of clinical trials comparing a treated group with a control group should be replaced either by statistically appropriate (but more complex) approaches or, preferably, by analyses which investigate the dependence of the treatment effect on measured baseline characteristics of the patients in each trial.
Statistical Methods in Medical ResearchControversies in meta-analysis: the case of the trials of serum cholesterol reduction
119 Citations1993SG Thompson
It is concluded that the long-term benefits of serum cholesterol reduction on the risk of heart disease have been seriously underestimated in some previous meta-analyses, while the evidence for adverse effects on other causes of death have been misleadingly exaggerated.
Cerebrovascular DiseasesEuropean Strategies for Early Intervention in Stroke (Part 1 of 2)
100 Citations2007Werner Hacke
Stroke is a major cause of death and disability in industrialized countries, but stroke awareness is still generally poor and treatment often ill-defined.
JAMAAnticoagulants Plus Streptokinase Therapy in Progressive Stroke
88 Citations1964John Stirling Meyer, John Gilroy +2 more
Intravenous Tissue Plasminogen Activator in Acute Thromboembolic Stroke: A Placebo-Controlled, Double-Blind Trial
64 Citations1993Takenori Yamaguchi, Tõru Hayakawa +1 more
A clinical trial of thrombolytic therapy in acute isChemic stroke prior to the appearance of ischemic findings on computed tomography (CT) is carried out.
Blood & Vessel
53 Citations1981Takeshi Abe, Mutsuyoshi Kazama +25 more
The availability and global improvement of TCUK were better than those of placebo in their statistical significance and the clinical effects were more significant in patient groups of mild or moderate grades in the severity of disorders.
QJMA pilot study of streptokinase for acute cerebral infarction
40 Citations1995A D Morris, Caroline Ritchie +3 more
Patients with acute stroke can be evaluated with CT and treated with streptokinase within 6 h, but the opportunity for treatment is currently limited to few patients.
PubMedOral urokinase: absorption, mechanisms of fibrinolytic enhancement and clinical effect on cerebral thrombosis.
8 Citations1986Takashi Abe
The results showed the usefulness of urokinase treatment, particularly in the early phase after the onset of stroke, particularly when the clinical effect was influenced by the plasma plasminogen level.